Navigation Links
Flexion's Lead Osteoarthritis Drug Candidate Demonstrates Significant, Prolonged Improvement in Pain and Function in Phase 2 Trial
Date:5/30/2012

WOBURN, Mass., May 30, 2012 /PRNewswire/ -- Flexion Therapeutics, Inc. today reported that its lead osteoarthritis drug candidate, FX005, demonstrated significant pain relief over placebo at four weeks* in a Phase 2 proof-of-concept trial. Top-line data showed FX005, delivered intra-articularly to the knee, was well-tolerated and resulted in prolonged improvement in joint pain and function throughout the 12-week duration of the study. These are the first-ever clinical results demonstrating the efficacy of a p38 MAP kinase inhibitor in osteoarthritis patients. Flexion plans to present the complete data set and analyses at an upcoming medical conference.

"There is considerable unmet need for treatments for the pain and damage caused by osteoarthritis," said Timothy McAlindon, chair of rheumatology and professor of medicine at Tufts Medical Center. "In particular, physicians and patients need targeted treatments for osteoarthritis that are more effective and longer lasting. These results represent a significant advance in that direction, so we will eagerly monitor development of this new treatment."

Michael Clayman, M.D., chief executive officer of Flexion, said, "We believe these data not only demonstrate the therapeutic potential of FX005 but also validate Flexion's approach to the treatment of osteoarthritis -- intra-articular delivery of sustained-release therapies providing prolonged activity at the site of disease while minimizing systemic exposure and the corresponding risk of systemic side effects. We are enthusiastic about advancing FX005 into the next phase of clinical development, which will be a Phase 2b dose-ranging study that we plan to initiate in the first half of 2013. The data from that study will then be used to identify an optimal dose for Phase 3."

The trial was a double-blind, placebo-controlled study in which 104 patients were randomized to receive FX005 or placebo via int
'/>"/>

SOURCE Flexion Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Evidence of Benefit Lacking for Many Common Ways of Treating Osteoarthritis of the Knee
2. Cost-Effectiveness Study Supports Use of EUFLEXXA(TM) by Rheumatologists for Pain Relief in Patients with Knee Osteoarthritis
3. Acologix Presents Preclinical Data on Cartilage Regeneration by AC-100 at the OARSI 2007 World Congress on Osteoarthritis
4. Osteoarthritis: Which Treatments Work and Which Dont?
5. Patients Taking Cymbalta(R) Reported Reduced Pain Severity of Osteoarthritis of the Knee in New Study
6. Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis
7. Interleukin Genetics to Present Important New Findings at 2008 World Congress on Osteoarthritis
8. Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period
9. ESBATechs Antibody Fragment Enters Phase I/IIa Clinical Development in Osteoarthritis with the Potential for Disease-Modifying Activity
10. Cymbalta(R) Significantly Reduced Osteoarthritis Knee Pain in New Study
11. New Treatment Against Osteoarthritis: Orthokine Therapy Highly Effective Against Knee Arthritis After Two Years
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... 22, 2014  - ... Today Lincor announced general availability of MediaLINC ... delivers a range of education, entertainment and clinical content ... (Logo: http://photos.prnewswire.com/prnh/20140822/702945) , " Lincor ... care patient engagement to bedside smart devices, " comments ...
(Date:8/22/2014)... Aug. 22, 2014  Cannabis Science, Inc. (OTC: ... drug development and related consulting, is pleased to ... medical cannabis conference taking place at the Faculty ... , on October 22, 2014.  The multilingual conference ... as researchers, health professionals, and patients, to discuss ...
(Date:8/22/2014)... Aug. 22, 2014  Landauer, Inc. (NYSE: ... radiation measurement and monitoring, outsourced medical physics services and ... William E. Saxelby , its President and Chief Executive ... Executive Officer and as a member of the Board ... will be replaced on an interim basis by ...
Breaking Medicine Technology:Lincor Unveils Next Generation TV-based Patient Engagement Solution 2Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 2Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 3Landauer, Inc. Announces Executive Management Change 2
... 15, 2011 PDI, Inc. (Nasdaq: ... promotional outsource services to established and emerging health care ... partnership with Qforma, the leading provider of advanced analytics ... Through this agreement, PDI will gain access ...
... REDWOOD CITY, Calif., March 15, 2011 – Ingenuity® ... solutions for life science researchers, today announced new ... in IPA®. Processed RNA-Seq datasets can now be ... context of pathways and diseases for a rich ...
Cached Medicine Technology:PDI Announces Exclusive Partnership With Qforma, Leading Provider of Advanced Analytics for Health Sciences Industry 2Ingenuity Announces RNA-Sequencing Workflow Support and First-of-Its-Kind microRNA Filtering Capability With Latest Release of IPA 2Ingenuity Announces RNA-Sequencing Workflow Support and First-of-Its-Kind microRNA Filtering Capability With Latest Release of IPA 3
(Date:8/22/2014)... The ALS Association, along with its Western Pennsylvania ... Health Network as a Certified Treatment Center of ... (AGH), is the only ALS treatment program in western ... highest levels of established national standards of care in ... to as Lou Gehrig’s Disease. , Allegheny Health Network’ ...
(Date:8/22/2014)... This funding was made through an additional ... Therapeutics, Inc. in the form of a convertible promissory ... collaborate with Saneron on several fronts to enable the ... to regenerative therapies using cord blood to ... Chairman and Co-CEO of Cryo-Cell, stated. He continued, ...
(Date:8/22/2014)... Human induced pluripotent stem cells (hiPSCs) have ... they can be coaxed to turn into specific cells; ... They sometimes mutate, develop into tumors or produce other ... published in STEM CELLS Translational Medicine, researchers appear to ... the material used to reprogram the stem cell after ...
(Date:8/22/2014)... 22, 2014 The New Jersey ... Rutgers, the State University of New Jersey has joined ... media organization, to educate young people about health and ... the strengths of both organizations. , The partnership will ... communications fellowship program, and video communications. ChopChop Magazine ...
(Date:8/22/2014)... air in American cities is getting safer to breathe, ... progress has been made in reducing levels of harmful ... said in a news release. Since 1990, there ... from human sources such as coal-fired plants, a 66 ... in lead, which harms brain development in children. ...
Breaking Medicine News(10 mins):Health News:Allegheny Health Network ALS Program Named Certified Treatment Center of Excellence 2Health News:Allegheny Health Network ALS Program Named Certified Treatment Center of Excellence 3Health News:Cryo-Cell Provides Funding for Cord Blood Clinical Trial Application to Treat ALS 2Health News:Cryo-Cell Provides Funding for Cord Blood Clinical Trial Application to Treat ALS 3Health News:Removing Programming Material After Inducing Stem Cells Could Improve Their Regeneration Ability 2Health News:New Jersey Institute for Food, Nutrition & Health to Launch Innovative Partnership with Award-Winning Children’s Anti-Obesity Organization, ChopChop Kids 2Health News:New Jersey Institute for Food, Nutrition & Health to Launch Innovative Partnership with Award-Winning Children’s Anti-Obesity Organization, ChopChop Kids 3Health News:Air in U.S. Cities Getting Cleaner, EPA Says 2
... Reporter , MONDAY, March 26 (HealthDay News) -- Here,s a ... who eat chocolate regularly are somewhat skinnier than folks who ... that chowing down on chocolate will melt off your excess ... modest difference in body mass, or it might be a ...
... honored with the Distinguished Sonographer Award during the 2012 ... at the JW Marriott Desert Ridge Resort and Spa ... Sonographer Award is a means of recognizing and honoring ... to the growth and development of medical ultrasound. ...
... Lisa Esposito HealthDay Reporter , THURSDAY, March ... initiative since the Medicare and Medicaid programs of the ... presidency, is about to face its biggest challenge. ... unprecedented six hours of arguments over three days on ...
... , MONDAY, March 26 (HealthDay News) -- ... leading cause of death among women in the United ... clinics, a new study suggests. Researchers from ... that heart screenings performed during visits to obstetrician/gynecologists could ...
... cancer researcher Professor Jane Visavader has been selected to ... The fellowship recognises Professor Visvader,s research over the past ... that can give rise to all types of cells ... which different types of breast cancer arise., Professor Visvader, ...
... offering in late March a new stereotactic radiosurgery ... available. The new imaging and radiosurgery ... fast and precise noninvasive image-guided radiation therapy. Radiosurgery ... with high precision to a tumor. "Radiosurgery ...
Cached Medicine News:Health News:Does Chocolate Help You Stay Slim? 2Health News:Does Chocolate Help You Stay Slim? 3Health News:Supreme Court Prepares to Tackle Affordable Care Act 2Health News:Supreme Court Prepares to Tackle Affordable Care Act 3Health News:Supreme Court Prepares to Tackle Affordable Care Act 4Health News:Supreme Court Prepares to Tackle Affordable Care Act 5Health News:Supreme Court Prepares to Tackle Affordable Care Act 6Health News:Ob/Gyn Visit a Good Time to Screen for Heart Disease: Study 2Health News:Professor Jane Visvader elected to Australian Academy of Science 2Health News:Cancer treatment system sculpts radiation beam to match shape of a tumor 2
... key challenges. Reducing costs while adjusting to ... Meeting ever-increasing expectations from more informed customers. ... with labor shortages. Providing value in managing ... theres targeted relief from a trusted partner ...
... The Roche Diagnostics Task Targeted ... state-of-the-art automation of pre- ... laboratories: decapping, sorting / archiving ... into bar code labeled secondary ...
... 20 years of experience in providing ... Life Sciences, the Freedom EVO platform ... for expansion according to future needs., ... Freedom EVOware, each system is equipped ...
... designed a flexible liquid handling system that ... three liquid handlers all on the same ... for targeted applications or custom-tailored to meet ... provide comprehensive systems that combine all the ...
Medicine Products: